The stock price of Xilio Therapeutics Inc (NASDAQ: XLO) has jumped by 12.38 compared to previous close of 1.05. Despite this, the company has seen a gain of 8.26% in its stock price over the last five trading days. Zacks Investment Research reported 2024-04-16 that Xilio (XLO) rallies 79.8% in a month on an exclusive global licensing agreement with Gilead Sciences to develop XTX301 for advanced solid tumors.
Is It Worth Investing in Xilio Therapeutics Inc (NASDAQ: XLO) Right Now?
The 36-month beta value for XLO is at -0.09. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for XLO is 8.72M, and currently, shorts hold a 4.35% of that float. The average trading volume for XLO on May 06, 2024 was 1.23M shares.
XLO’s Market Performance
XLO stock saw a decrease of 8.26% in the past week, with a monthly decline of -2.48% and a quarterly a decrease of 79.06%. The volatility ratio for the week is 11.53%, and the volatility levels for the last 30 days are 12.46% for Xilio Therapeutics Inc (XLO). The simple moving average for the past 20 days is 0.25% for XLO’s stock, with a -20.94% simple moving average for the past 200 days.
Analysts’ Opinion of XLO
Many brokerage firms have already submitted their reports for XLO stocks, with Chardan Capital Markets repeating the rating for XLO by listing it as a “Buy.” The predicted price for XLO in the upcoming period, according to Chardan Capital Markets is $7 based on the research report published on December 21, 2022 of the previous year 2022.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see XLO reach a price target of $36. The rating they have provided for XLO stocks is “Buy” according to the report published on January 10th, 2022.
Raymond James gave a rating of “Outperform” to XLO, setting the target price at $31 in the report published on November 16th of the previous year.
XLO Trading at 24.26% from the 50-Day Moving Average
After a stumble in the market that brought XLO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.69% of loss for the given period.
Volatility was left at 12.46%, however, over the last 30 days, the volatility rate increased by 11.53%, as shares sank -1.67% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +114.55% upper at present.
During the last 5 trading sessions, XLO rose by +8.26%, which changed the moving average for the period of 200-days by -55.64% in comparison to the 20-day moving average, which settled at $1.1760. In addition, Xilio Therapeutics Inc saw 114.55% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at XLO starting from GILEAD SCIENCES, INC., who purchase 485,250 shares at the price of $0.76 back on Apr 02 ’24. After this action, GILEAD SCIENCES, INC. now owns 7,345,473 shares of Xilio Therapeutics Inc, valued at $368,790 using the latest closing price.
Atlas Venture Fund XI, L.P., the 10% Owner of Xilio Therapeutics Inc, sale 733 shares at $0.64 during a trade that took place back on Feb 08 ’24, which means that Atlas Venture Fund XI, L.P. is holding 2,019,563 shares at $469 based on the most recent closing price.
Stock Fundamentals for XLO
The total capital return value is set at -1.76. Equity return is now at value -107.25, with -76.37 for asset returns.
Based on Xilio Therapeutics Inc (XLO), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -15.53. The debt to equity ratio resting at 0.12. The interest coverage ratio of the stock is 90.03.
Currently, EBITDA for the company is -77.23 million with net debt to EBITDA at 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.02.
Conclusion
In conclusion, Xilio Therapeutics Inc (XLO) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
